STOCK TITAN

Ginkgo Bioworks Holdings, Inc. - $DNA STOCK NEWS

Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: $DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ginkgo Bioworks Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ginkgo Bioworks Holdings's position in the market.

Rhea-AI Summary
Ginkgo Bioworks announces Q2 2023 results, adding 21 new Cell Programs to the Foundry platform and ending the quarter with $1.1 billion in cash. The company highlights continued success with expanded relationships with Sumitomo, Novo Nordisk, and Merck. Ginkgo's Cell Engineering segment generated $44 million in revenue, a 72% increase from Q2 2022. Ginkgo's Biosecurity segment generated $35 million in revenue. Shyam Sankar appointed as Chair of Ginkgo's Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.94%
Tags
-
Rhea-AI Summary
Ginkgo Bioworks announces a new collaboration with Merck focused on improving biologic manufacturing. Ginkgo will utilize its expertise in cell engineering and process optimization to increase production efficiency. The collaboration could result in up to $490 million in upfront and milestone payments for Ginkgo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
-
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) and the Government of the Republic of Panama's Gorgas Memorial Institute for Health Studies have signed a Memorandum of Understanding to develop new biosecurity capabilities in Latin America. Concentric by Ginkgo will support the Gorgas Institute in strengthening Panama's biosecurity infrastructure, with a focus on detecting, identifying, and monitoring pathogens. The collaboration will include efforts in wastewater surveillance, lab enablement, and bioinformatics analysis, with strategic locations in urban centers and ports-of-entry. This partnership aims to enhance Panama's COVID-19 and novel pathogen detection infrastructure, as well as contribute to regional pandemic preparedness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.82%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.09%
Tags
none
-
Rhea-AI Summary
Sumitomo Chemical and Ginkgo Bioworks announce a new program to develop functional chemicals with synthetic biology. The companies aim to enable mass production of functional chemicals via fermentation, providing products with a lower carbon footprint.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
partnership
Rhea-AI Summary
Ginkgo Bioworks and the Ministry of Health of Botswana have announced a pathogen monitoring program at key ports of entry to identify new variants of SARS-CoV-2. The program will monitor wastewater and nasal swab samples from arriving international travelers. The collaboration aims to establish Sir Seretse Khama International Airport as a new node in a global network of pathogen monitoring infrastructure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.86%
Tags
none
-
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) awarded research contract from IARPA for Biointelligence and Biosecurity for the Intelligence Community (B24IC) program. Aims to develop biosensor for improved traceability and biosecurity through recording time-ordered cellular memory. The tool would function as a synthetic memory device, registering cellular histories to support investigations into origination, attribution, and specific use. Ginkgo's computational design capabilities can provide the B24IC program with the needed expertise to realize this project's goal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

DNA Rankings

DNA Stock Data

1.46B
1.12B
6.74%
83.82%
12.58%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BOSTON

About DNA

the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.